Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Five Prime Therapeutics stock
Own Five Prime Therapeutics stock in just a few minutes.
Five Prime Therapeutics, Inc is a biotechnology business based in the US. Five Prime Therapeutics shares (FPRX) are listed on the NASDAQ and all prices are listed in US Dollars. Five Prime Therapeutics employs 51 staff and has a trailing 12-month revenue of around USD$13.2 million.
How to buy shares in Five Prime Therapeutics
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Five Prime Therapeutics. Find the stock by name or ticker symbol: FPRX. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Five Prime Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Five Prime Therapeutics, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Five Prime Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
Five Prime Therapeutics share price
Use our graph to track the performance of FPRX stocks over time.Five Prime Therapeutics shares at a glance
Information last updated 2021-04-08.
| 52-week range | USD$2.61 - USD$38.9 |
|---|---|
| 50-day moving average | USD$33.0974 |
| 200-day moving average | USD$18.3107 |
| Wall St. target price | USD$37.17 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-4.486 |
Buy Five Prime Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Five Prime Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is Five Prime Therapeutics under- or over-valued?
Valuing Five Prime Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Five Prime Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Five Prime Therapeutics's PEG ratio
Five Prime Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.14. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Five Prime Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Five Prime Therapeutics financials
| Revenue TTM | USD$13.2 million |
|---|---|
| Gross profit TTM | USD$-43,243,000 |
| Return on assets TTM | -17.19% |
| Return on equity TTM | -40.58% |
| Profit margin | 0% |
| Book value | $5.782 |
| Market capitalisation | USD$1.8 billion |
TTM: trailing 12 months
Shorting Five Prime Therapeutics shares
There are currently 1.9 million Five Prime Therapeutics shares held short by investors – that's known as Five Prime Therapeutics's "short interest". This figure is 33.1% down from 2.8 million last month.
There are a few different ways that this level of interest in shorting Five Prime Therapeutics shares can be evaluated.
Five Prime Therapeutics's "short interest ratio" (SIR)
Five Prime Therapeutics's "short interest ratio" (SIR) is the quantity of Five Prime Therapeutics shares currently shorted divided by the average quantity of Five Prime Therapeutics shares traded daily (recently around 4.0 million). Five Prime Therapeutics's SIR currently stands at 0.48. In other words for every 100,000 Five Prime Therapeutics shares traded daily on the market, roughly 480 shares are currently held short.
However Five Prime Therapeutics's short interest can also be evaluated against the total number of Five Prime Therapeutics shares, or, against the total number of tradable Five Prime Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Five Prime Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Five Prime Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.048% of the tradable shares (for every 100,000 tradable Five Prime Therapeutics shares, roughly 48 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Five Prime Therapeutics.
Find out more about how you can short Five Prime Therapeutics stock.
Five Prime Therapeutics share dividends
We're not expecting Five Prime Therapeutics to pay a dividend over the next 12 months.
Five Prime Therapeutics share price volatility
Over the last 12 months, Five Prime Therapeutics's shares have ranged in value from as little as $2.61 up to $38.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Five Prime Therapeutics's is 4.6271. This would suggest that Five Prime Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Five Prime Therapeutics overview
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of immuno-oncology and targeted cancer therapies. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b to treat patients with gastric or gastroesophageal junction and GEJ cancer; FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that is in Phase Ia/1b clinical trial for patients with solid tumors; and BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase I/II clinical trial in combination with Opdivo in patients with advanced malignant tumors. Its preclinical programs include FPA157, an anti-CCR8 antibody that is engineered to eliminate CCR8-expressing CD4+ regulatory T cells within solid tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, and BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.
Frequently asked questions
More guides on Finder
-
How to buy PrimeEnergy Resources Corporation stock
Steps to owning and managing PNRG, with 24-hour and historical pricing before you buy.
-
How to buy Premier stock
Steps to owning and managing PINC, with 24-hour and historical pricing before you buy.
-
How to buy Predictive Oncology stock
Steps to owning and managing POAI, with 24-hour and historical pricing before you buy.
-
How to buy Powerbridge Technologies CoLtd stock
Steps to owning and managing PBTS, with 24-hour and historical pricing before you buy.
-
How to buy Portman Ridge Finance Corporation stock
Steps to owning and managing PTMN, with 24-hour and historical pricing before you buy.
-
How to buy Popular stock
Steps to owning and managing BPOP, with 24-hour and historical pricing before you buy.
-
How to buy Playa Hotels-and-Resorts N-V stock
Steps to owning and managing PLYA, with 24-hour and historical pricing before you buy.
-
How to buy Plains GP Holdings L-P stock
Steps to owning and managing PAGP, with 24-hour and historical pricing before you buy.
-
How to buy Plains All American Pipeline L-P stock
Steps to owning and managing PAA, with 24-hour and historical pricing before you buy.
-
How to buy Property Solutions Acquisition stock
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Ask an Expert